Literature DB >> 9792150

Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases.

C Fordy1, C Glover, M M Davies, T G Allen-Mersh.   

Abstract

Hepatic arterial floxuridine (HAI) in 35 patients with systemic fluorouracil/folinic acid-resistant colorectal liver metastases achieved a 14% partial response and 26% disease stabilization rate, with a median response duration of 7 months from onset of HAI.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9792150      PMCID： PMC2063159          DOI： 10.1038/bjc.1998.627

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  23 in total

1.  A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.

Authors:  W D Ensminger; A Rosowsky; V Raso; D C Levin; M Glode; S Come; G Steele; E Frei
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

2.  Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.

Authors:  Y Z Patt; A Hoque; R Lozano; R Pozdur; J Chase; H Carrasco; V Chuang; E S Delpassand; L Ellis; S Curley; M Roh; D V Jones
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

3.  The Sickness Impact Profile: development and final revision of a health status measure.

Authors:  M Bergner; R A Bobbitt; W B Carter; B S Gilson
Journal:  Med Care       Date:  1981-08       Impact factor: 2.983

4.  Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients.

Authors:  S Earlam; C Glover; M Davies; C Fordy; T G Allen-Mersh
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

5.  Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

Authors:  P Rougier; R Bugat; J Y Douillard; S Culine; E Suc; P Brunet; Y Becouarn; M Ychou; M Marty; J M Extra; J Bonneterre; A Adenis; J F Seitz; G Ganem; M Namer; T Conroy; S Negrier; Y Merrouche; F Burki; M Mousseau; P Herait; M Mahjoubi
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

6.  Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

Authors:  M L Rothenberg; J R Eckardt; J G Kuhn; H A Burris; J Nelson; S G Hilsenbeck; G I Rodriguez; A M Thurman; L S Smith; S G Eckhardt; G R Weiss; G L Elfring; D A Rinaldi; L J Schaaf; D D Von Hoff
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544

7.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

8.  Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial.

Authors:  N Kemeny; J Daly; B Reichman; N Geller; J Botet; P Oderman
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

9.  Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines.

Authors:  C H Jenh; P K Geyer; F Baskin; L F Johnson
Journal:  Mol Pharmacol       Date:  1985-07       Impact factor: 4.436

10.  Hepatic arterial cannulation for regional chemotherapy is safe in patients with a liver metastasis volume of less than 1 litre.

Authors:  D Burke; C Fordy; S A Earlam; T G Allen-Mersh
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640
View more
  1 in total

1.  In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens.

Authors:  Waleed Younis; Ahmed AbdelKhalek; Abdelrahman S Mayhoub; Mohamed N Seleem
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.